Developing targeted compounds to enhance D5 receptor activity for cognitive improvement
Small-molecule probes for augmenting D5 receptor signaling
This study is looking at new ways to help people with neuropsychiatric disorders improve their thinking and memory by creating special medications that focus on a specific brain receptor, which could lead to better treatments with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lieber Institute, INC. NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10992646 on NIH RePORTER |
What this research studies
This research focuses on improving cognitive function in patients with neuropsychiatric disorders by developing small-molecule probes that selectively target the D5 dopamine receptor. The approach involves designing and synthesizing compounds that can enhance D5 receptor signaling, which has been shown to play a critical role in cognitive processes. By identifying these selective ligands, the research aims to better understand the specific effects of D5 receptor activation and reduce adverse effects associated with current treatments. Patients may benefit from more effective therapies that specifically target cognitive dysfunction without the drawbacks of non-selective agonists.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing cognitive decline associated with neuropsychiatric conditions.
Not a fit: Patients with cognitive impairment not related to neuropsychiatric disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cognitive impairment in neuropsychiatric disorders.
How similar studies have performed: Previous research has shown promising results with D1/D5 receptor agonists, but this approach to developing D5-selective compounds is relatively novel.
Where this research is happening
Baltimore, United States
- Lieber Institute, INC. — Baltimore, United States (Active)
Researchers
- Principal investigator: Carr, Gregory V — Lieber Institute, INC.
- Study coordinator: Carr, Gregory V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.